Abstract
Technological advances in the past decade have shifted revascularization strategies from traditional open surgical approaches toward lower-morbidity percutaneous endovascular treatments for patients with lower extremity peripheral arterial disease (PAD). The continuing advances in stent design, more than any other advances, have fueled the growth of catheter-based procedures by improving the safety, durability, and predictability of percutaneous revascularization. Although the 2007 TransAtlantic Inter-Society Consensus (TASC) guidelines recommend endovascular therapy for type A and B aortoiliac and femoropopliteal lesions, recent developments in stent technology and increased experience of interventionists have suggested that a strategy of endovascular therapy first is appropriate in experienced hands for TASC type D lesions. The role of endovascular interventions is also expanding in the treatment of limb-threatening ischemia.
Similar content being viewed by others
References
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–67.
Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47(6):1239–312.
Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71(3):510–51.
Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995;91(5):1472–9.
Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110(6):738–43.
Isner J, Rosenfield K. Redefining the treatment of peripheral artery disease: role of percutaneous revascularization. Circulation. 1993;88:1534–57.
Holm J, Arfvidsson B, Jivegard L, Lundgren F, Lundhom K, Scherten T, et al. Chronic lower limb ischaemia: a prospective randomized controlled study comparing the 1-year results of vascular surgery and percutaneous transluminal angioplasty (PTA). Eur J Vasc Surg. 1991;5:517–22.
Wilson SE, Wolf GL, Cross AP. Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis: report of a prospective randomized trial in a selected group of patients. J Vasc Surg. 1989;9:1–9.
Dormandy JA, Rutherford RB, for the TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). Management of peripheral arterial disease (PAD). J Vasc Surg. 2000;31:S1–296.
Jamsen T, Manninen H, Tulla H, Matsi P. The final outcome of primary infrainguinal percutaneous transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia. J Vasc Interv Radiol. 2002;13:455–63.
Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. 1997;204:87–96.
Galaria II, Davies MG. Percutaneous transluminal revascularization for iliac occlusive disease: long-term outcomes in TransAtlantic Inter-Society Consensus A and B lesions. Ann Vasc Surg. 2005;19:352–60.
Timaran CH, Prault TL, Stevens SL, Freeman MB, Goldman MH. Iliac artery stenting versus surgical reconstruction for TASC (TransAtlantic Inter-Society Consensus) type B and type C iliac lesions. J Vasc Surg. 2003;38:272–8.
Kashyap VS, Pavkov ML, Bena JF, Sarac TP, O’Hara PJ, Lyden SP, et al. The management of severe aortoiliac occlusive disease: endovascular therapy rivals open reconstruction. J Vasc Surg. 2008;48:1451–7.
Hans SS, DeSantis D, Siddiqui R, Khoury M. Results of endovascular therapy and aortobifemoral grafting for Transatlantic Inter-Society type C and D aortoiliac occlusive disease. Surgery. 2008;144:583–9.
Klein WM, van der Graaf Y, Seegers J, Spithoven JH, Buskens E, van Baal JG, et al. Dutch iliac stent trial: long-term results in patients randomized for primary or selective stent placement. Radiology. 2006;238:734–44.
Bosch JL, Hunink MG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. 1997;204(1):87–96.
Ponec D, Jaff MR, Swischuk J, Feiring A, Laird J, Mehra M, et al. The Nitinol SMART stent vs Wallstent for suboptimal iliac artery angioplasty: CRISP-US trial results. J Vasc Interv Radiol. 2004;15(9):911–8.
Sixt S, Alawied AK, Rastan A, Schwarzwalder U, Kleim M, Noory E, et al. Acute and long-term outcome of endovascular therapy for aortoiliac occlusive lesions stratified according to the TASC classification: a single center experience. J Endovasc Ther. 2008;15:408–16.
Park KB, Do YS, Kim JH, Han YH, Kim DI, Kim DK, et al. Stent placement for chronic iliac arterial occlusive disease: the results of 10 years experience in a single institution. Korean J Radiol. 2005;6:256–66.
Sharafuddin MJ, Hoballah JJ, Kresowik TF, Sharp WJ. Kissing stent reconstruction of the aortoiliac bifurcation. Perspect Vasc Surg Endovasc Ther. 2008;20:50–60.
Scheinert D, Schroder M, Ludwig J, Braunlich S, Mockel M, Flachskampf FA, et al. Stent-supported recanalization of chronic iliac artery occlusions. Am J Med. 2001;110:708–15.
Bjorses K, Ivancev K, Riva L, Manjer J, Uher P, Resch T. Kissing stents in the aortic bifurcation: a valid reconstruction for aorto-iliac occlusive disease. Eur J Vasc Endovasc Surg. 2008;36:424–31.
De Roeck A, Hendriks JM, Delrue F, Lauwers P, Van Schil P, De Maeseneer M, et al. Long-term results of primary stenting for long and complex iliac artery occlusions. Acta Chir Belg. 2006;106:187–92.
Greiner A, Dessl A, Klein-Weigel P, Neuhauser B, Perkmann R, Waldenberger P, et al. Kissing stents for treatment of complex aortoiliac disease. Eur J Vasc Endovasc Surg. 2003;26:161–5.
Kudo T, Chandra FA, Ahn SS. Long-term outcomes and predictors of iliac angioplasty with selective stenting. J Vasc Surg. 2005;42(3):466–75.
Higashiura W, Kubota Y, Sakaguchi S, Kurumatani N, Nakamae M, Nishimine K, Kichikawa K. Prevalence, factors, and clinical impact of self-expanding stent fractures following iliac artery stenting. J Vasc Surg. 2009;49(3):645–52.
Jongkind V, Akkersdijk GJ, Yeung KK, Wisselink W. A systematic review of endovascular treatment of extensive aortoiliac occlusive disease. J Vasc Surg. 2010;52(5):1376–83.
Lammer J, Dake MD, Bleyn J, Katzen BT, Cejna M, Piquet P, Becker GJ, Settlage RA. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent-graft. International Trial Study Group. Radiology. 2000;217:95–104.
Rzucidlo EM, Powell RJ, Zwolak RM, et al. Early results of stent-grafting to treat diffuse aortoiliac occlusive disease. J Vasc Surg. 2003;37:1175–80.
Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–88.
Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745–9.
Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv. 2009;74(7):1090–5.
Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al., RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3):267–76.
Krankenberg H, Schluter M, Steinkamp H, Burgelin K, Scheinert D, Schulte KL, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285–92.
Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation. 2002;106(12):1505–9.
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16(3):331–8.
Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54(2):394–401.
Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4(5):495–504.
Sabeti S, Mlekusch W, Amighi J, et al. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J Endovasc Ther. 2005;12(1):6–12.
Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45(2):312–5.
Saxon RR, Dake MD, Volgelzang RL, Katzen BT, Becker GJ. Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. J Vasc Int Radiol. 2008;19(6):823–32.
Jahnke T, Andresen R, Müller-Hülsbeck S, et al. Hemobahn stent-grafts for treatment of femoropopliteal arterial obstructions: midterm results of a prospective trial. J Vasc Int Radiol. 2003;14(1):41–51.
Fischer M, Schwabe C, Schulte K-L. Value of the Hemobahn/Viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. J Endovasc Ther. 2006;13(3):281–90.
Saxon RR, Coffman JM, Gooding JM, Ponec DJ. Long-term patency and clinical outcome of the VIABAHN Stent-Graft for femoropopliteal artery obstructions. J Vasc Interv Radiol. 2007;18(11):1341–50.
Kedora J, Hohmann S, Garrett W, et al. Randomized comparison of percutaneous Viabahn stent grafts vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral arterial occlusive disease. J Vasc Surg. 2007;45(1):10–6.
Ansel GM, Botti CF, Silver MJ. The use of femoropopliteal stent-grafts for critical limb ischemia. Tech Vasc Interv. 2005;8(4):140–5.
McQuade K, Gable D, Hohman S, Pearl G, Theune B. Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg. 2009;49(1):109–16.
Lenti M, Cieri E, De Rango P, et al. Endovascular treatment of long lesions of the superficial femoral artery: results from a multicenter registry of a spiral, covered polytetrafluoroethylene stent. J Vasc Surg. 2007;45(1):32–9.
Knight JS, Smeets L, Morris GE, Moll FL. Multi centre study to assess the feasibility of a new covered stent and delivery system in combination with remote superficial femoral artery endarterectomy (RSFAE). Eur J Vasc Endovasc Surg. 2005;29(3):287–94.
Rosenthal D, Martin JD, Schubart PJ, Wellons ED. Remote superficial femoral artery endarterectomy. J Cardiovasc Surg (Torino). 2004;45(3):185–92.
Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Boehm M, Hamm B. Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology. 2006;240(2):411–8.
Scheller B, Speck U. Solutions and future perspectives: potential solutions to the current problem. Coated balloon. Eurointervention. 2008;4(Suppl C):C63–6.
Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689–99.
Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G, Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon. Femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13):1358–65.
Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47(5):975–81.
Rand T, Basile A, Cejna M, Fleischmann D, Funovics M, Gschwendtner M, et al. PTA versus carbofilm-coated stents in infrapopliteal arteries: pilot study. Cardiovasc Intervent Radiol. 2006;29(1):29–38.
Scheinert D, Ulrich M, Scheinert S, Sax J, Bräunlich S, Biamino G. Comparison of sirolimus-eluting vs. bare-metal stents for the treatment of infrapopliteal obstructions. Eurointervention. 2006;2:169–74.
Commeau P, Barragan P, Roquebert PO. Sirolimus for below the knee lesions: mid-term results of SiroBTK study. Cathet Cardiovasc Interv. 2006;68:793–8.
Siablis D, Kraniotis P, Karnabatidis D, Kagadis GC, Katsanos K, Tsolakis J. Sirolimus-eluting versus bare metal stents for bailout after suboptimal infrapopliteal angioplasty for chronic limb ischemia: 6 month angiographic results from a nonrandomized prospective single-center study. J Endovasc Ther. 2005;12:685–95.
Siablis D, Karnabatidis D, Katsanos K, et al. Sirolimus-eluting versus bare stents for after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. J Endovasc Ther. 2007;14:241–50.
Siablis D, Karnabatidis D, Katsanos K, et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol. 2009;20:1141–50.
Rastan A, Tepe G, Krankenberg H, Zahorsky R, Beschorner U, Noory E, et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011;32(18):2274–81.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kudagi, V.S., White, C.J. Endovascular Stents: A Review of Their Use in Peripheral Arterial Disease. Am J Cardiovasc Drugs 13, 199–212 (2013). https://doi.org/10.1007/s40256-013-0023-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40256-013-0023-6